country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P991581

Copy Link Print Information

Biologically Validated

MK-2060

Name: MK-2060
Brand: MedChemExpress
SKU: HY-P991581
Price: 320.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Avis client

Based on 1 Customer Validation

MK-2060 is a monoclonal antibody factor XI inhibitor. MK-2060 binds to the A3 domain of coagulation factor XI (FXI), prevents FXIIa-mediated FXI activation, and blocks the binding/activation of FIX with FXIa, locking the zymogen in an inactive/non-activatable conformation, thereby prolonging aPTT. MK-2060 can be used in research on end-stage renal disease, ESRD requiring hemodialysis, and arteriovenous graft thrombosis.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : ≥99.0%
CAS No.: 2812480-88-7
Masse moléculaire:145.33 kDa

Stockage:

Shipping with dry ice

Please store the product under the recommended conditions in the Certificate of Analysis.

MK-2060 Chemical Structure

CAS No.: 2812480-88-7

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- Essai clinique
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Application
- Verified Bioactivity
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Isotype

Human IgG4 kappa

Recommend Isotype Controls

Human IgG4 (S228P) kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

F11/Factor XI

In Vitro

MK-2060 binds to the A3 domain of FXI, prevents FXIIa from activating FXI, and blocks the binding of FIX to FXIa; it belongs to the class of antibodies that lock the zymogen FXI in an inactive conformation, producing a state resembling FXI deficiency^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Gene ID

2160 [NCBI]

Accession

P03951

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Application

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized Human Factor XI Protein, His Tag can bind MK-2060. The EC₅₀ for this effect is 59.5 ng/mL.

Chemical Information

CAS No. 2812480-88-7
Appearance Liquid
Masse moléculaire 145.33 kDa
Color Colorless to light yellow
SMILES

N/A
Livraison

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (272 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Références

[1]. Presume J, et al. Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy. Cardiology and therapy. 2024 Mar;13(1):1-16.

[2]. Jin M, et al. Potential Role of Contact Pathway Factors in Catheter-Related Thrombosis: Emerging Evidence and Therapeutic Strategies. Biomolecules. 2026 Aug 29;16(9):1256.

[3]. Holzhauer S, et al. Factor XI Inhibition: Adult Evidence and Paediatric Considerations. Hamostaseologie. 2026 Aug 07.

[4]. De Caterina R, et al. Factor XI inhibitors: cardiovascular perspectives. European heart journal. 2023 Jan 21;44(4):280-292. [Content Brief]

[5]. Gailani D, et al. Measuring up: the need for new assays for factor (F) XI/FXIa inhibitor therapies[J]. Research and Practice in Thrombosis and Haemostasis, 2026.

[6]. Del Toro-Mijares R, et al. Venous thromboembolism prevention and treatment with factor XI/XIa inhibitors: current status and future perspectives. Journal of thrombosis and thrombolysis. 2026 Jan;59(1):23-34.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis